Intelligent Bio Solutions Inc.

NasdaqCM:INBS Stock Report

Market Cap: US$6.1m

Intelligent Bio Solutions Balance Sheet Health

Financial Health criteria checks 4/6

Intelligent Bio Solutions has a total shareholder equity of $5.9M and total debt of $499.6K, which brings its debt-to-equity ratio to 8.4%. Its total assets and total liabilities are $11.7M and $5.8M respectively.

Key information

8.4%

Debt to equity ratio

US$499.61k

Debt

Interest coverage ration/a
CashUS$3.99m
EquityUS$5.95m
Total liabilitiesUS$5.78m
Total assetsUS$11.73m

Recent financial health updates

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Jul 29
Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Recent updates

GBS acquires Intelligent Fingerprinting in all-stock deal

Oct 04

GBS GAAP EPS of -$0.57, revenue of $0.44M

Aug 31

GBS Inc.: Can Its Technology Come Through?

Aug 31

GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing

Aug 09

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Jul 29
Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Financial Position Analysis

Short Term Liabilities: INBS's short term assets ($6.5M) exceed its short term liabilities ($5.7M).

Long Term Liabilities: INBS's short term assets ($6.5M) exceed its long term liabilities ($97.8K).


Debt to Equity History and Analysis

Debt Level: INBS has more cash than its total debt.

Reducing Debt: INBS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INBS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: INBS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.9% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 05:57
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Intelligent Bio Solutions Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey CohenLadenburg Thalmann & Company
John VandermostenZacks Small-Cap Research